A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

George I. Papakostas, MD; Ottavio V. Vitolo, MD; Waguih W. IsHak, MD; Mark H. Rapaport, MD; John M. Zajecka, MD; Gustavo Kinrys, MD; David Mischoulon, MD; Samuel H. Lipkin, BA; Katherine A. Hails, BA; Jonah Abrams, BA; Sean G. Ward, MBA; Allison Meisner, MA; David A. Schoenfeld, PhD; Richard C. Shelton, MD; Andrew Winokur, MD; Mahmoud S. Okasha, MD; Mohammed A. Bari, MD; and Maurizio Fava, MD

Published: December 15, 2012

Article Abstract

Objective: To study ziprasidone monotherapy for major depressive disorder, defined according to the DSM-IV.

Method: One hundred twenty outpatients were enrolled between June 2008 and September 2010 in a 12-week study that was divided into two 6-week periods according to the sequential parallel comparison design. Patients were randomized in a 2:3:3 fashion to receive ziprasidone for 12 weeks, placebo for 6 weeks followed by ziprasidone for 6 weeks, or placebo for 12 weeks. The main outcome measure was the 17-item Hamilton Depression Rating Scale (HDRS-17), with the Quick Inventory of Depressive Symptomatology, Self-Rated (QIDS-SR), and Clinical Global Impressions-Severity of Illness scale (CGI-S) serving as the study secondary measures.

Results: One hundred twenty patients (53 women [44.1%]) were randomized to treatment. The mean (SD) age of these patients was 43.7 (11.0) years. Mean (SD) baseline HDRS-17, CGI-S, and QIDS-SR scores were 19.9 (5.0), 4.3 (0.6), and 15.6 (3.0), respectively. There was no statistically significant difference in reduction of depressive symptoms, response rates, or remission rates between ziprasidone- or placebo-treated patients. This was true for both the study primary as well as secondary outcome scales.

Conclusions: In conclusion, treatment with ziprasidone monotherapy was not associated with any statistically significant advantage in efficacy over placebo. Although studies involving larger sample size would be required to have adequate statistical power to detect treatment differences smaller than 2.5 points on the HDRS-17, such differences would be of questionable clinical relevance.

Trial Registration: ClinicalTrials.gov identifier: NCT00555997

J Clin Psychiatry 2012;73(12):1541-1547

 

 

Submitted: January 24, 2012; accepted August 15, 2012(doi:10.4088/JCP.12m07670).

 

Corresponding author: George I. Papakostas, MD, Center for Treatment-Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, One Bowdoin Sq, 6th Floor, Boston, MA 02114 (gpapakostas@partners.org).

Volume: 73

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...